Abstract
This study investigated the effectiveness of a nonoxynol-9 (52.5mg, 3.5%), vaginal gel (Advantage S), in the prevention of human papillomavirus (HPV) infection in female sex workers. We showed by HPV DNA determination in cervico-vaginal rinses a significant increase in multiple (>1) HPV infection in HIV-1 seropositive women compared with HIV-1 seronegative women (OR 4.0, 95% CI 1.3-11.9). We also demonstrated a significant increase in multiple HPV infections in HIV-1 seronegative women using nonoxynol-9 compared with HIV-1 seronegative women using placebo (OR 3.5 95% CI 1.0-11.8). We conclude that the use of nonoxynol-9 did not prevent genital HPV infection and could increase the virus' ability to infect or persist.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Administration, Intravaginal
-
Cervix Uteri / virology
-
Cohort Studies
-
Confounding Factors, Epidemiologic
-
DNA, Viral / analysis
-
Female
-
HIV Seropositivity / complications
-
HIV Seropositivity / epidemiology
-
HIV-1
-
Humans
-
Nonoxynol / administration & dosage*
-
Papillomaviridae / drug effects*
-
Papillomaviridae / genetics
-
Papillomaviridae / isolation & purification
-
Papillomavirus Infections / complications
-
Papillomavirus Infections / prevention & control
-
Sex Work
-
South Africa / epidemiology
-
Spermatocidal Agents / administration & dosage*
-
Treatment Outcome
-
Uterine Cervical Neoplasms / complications
-
Uterine Cervical Neoplasms / prevention & control
-
Vaginal Creams, Foams, and Jellies / administration & dosage
Substances
-
DNA, Viral
-
Spermatocidal Agents
-
Vaginal Creams, Foams, and Jellies
-
Nonoxynol